MAM
AKCA

Meeder Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Meeder Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-813
Closed -$12K – 2486
2020
Q2 		$12K Sell
813
-2,601
-76% -$40.1K ﹤0.01% 1282
2020
Q1 		$48K Buy
3,414
+2,675
+362% +$43.9K ﹤0.01% 932
2019
Q4 		$12K Buy
+739
New +$13.8K ﹤0.01% 1524
2019
Q2 		– Sell
-217
Closed -$6K – 2205
2019
Q1 		$6K Buy
+217
New +$6.32K ﹤0.01% 1379
2018
Q4 		– Sell
-66
Closed -$2K – 1861
2018
Q3 		$2K Buy
+66
New +$2K ﹤0.01% 1459

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's AKCA Position: Q3 2020 in Review

Meeder Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 813 shares — an estimated $12K sold.

Meeder Asset Management first reported a position in AKCA in Q3 2018 and held it in 5 quarters. The position peaked at $48K in Q1 2020. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

  • Meeder Asset Management reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Meeder Asset Management sold 813 Akcea Therapeutics Inc shares in Q3 2020, an estimated $12K.
  • Meeder Asset Management first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 5 quarters.
  • Meeder Asset Management's Akcea Therapeutics Inc position peaked at $48K in Q1 2020.
  • 98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.